RHHBY Roche Holding Ltd ADR (Sponsored)

35.19
-0.2  -1%
Previous Close 35.38
Open 35.48
Price To Book 8.5
Market Cap 240,375,774,019
Shares 6,830,797,784
Volume 2,977,244
Short Ratio
Av. Daily Volume 1,176,528

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 interim data due 1H 2019.
Mytesi (crofelemer) HALT-D
Cancer related diarrhea (CRD)
Phase 3 data did not meet primary endpoint - June 20, 2019.
IMspire170 - cobimetinib and atezolizumab
First-line BRAF wild-type metastatic or unresectable locally advanced melanoma
First patient enrolled in Phase 3 trial announced January 28, 2019.
IONIS-HTT Rx
Huntington's Disease
Phase 3 data released May 10, 2018. Primary endpoint not met.
IMblaze370 - cobimetinib and atezolizumab
Third-line advanced or metastatic colorectal cancer
Phase 3 trial terminated following interim analysis indicating primary endpoint would not be met.
Crenezumab - CREAD 2
Alzheimer’s disease
Primary endpoint was met March 2, 2017. Data released June 5, 2017 - HR 0.81. Disease-free-survival +0.9% over Herceptin.
Perjeta + Herceptin (APHINITY)
Adjuvant HER2+ breast cancer
Approval announced June 11, 2018.
Venclexta (MURANO)
Relapsed or refractory Chronic Lymphocytic Leukemia (CLL)
NDA filing due 2H 2019.
RG7916 - SUNFISH
Spinal Muscular Atrophy (SMA)
Phase 3 trial terminated following interim analysis indicating primary endpoint would not be met.
Crenezumab - CREAD 1
Alzheimer’s disease
Phase 3 data due in 2020.
Kadcyla (KAITLIN)
HER2-positive breast cancer - adjuvant use
FDA approval announced May 6, 2019.
Kadcyla (KATHERINE)
HER2-positive breast cancer - residual invasive disease
PDUFA date under priority review August 18, 2019.
Entrectinib
Solid tumors and ROS1-positive non-small cell lung cancer (NSCLC)
Phase 3 PFS endpoint met - PFS=6.3 vs. 5.6 months for chemo. HR 0.71.
Tecentriq+cb+pac/nab-pac - IMpower131
Squamous non-small cell lung cancer (NSCLC)
FDA Approval announced December 6, 2018.
Tecentriq + Avastin - IMpower150
Non-squamous non-small cell lung cancer (NSCLC)
PFS endpoint met. HR 0.74 - February 6, 2018.
TECENTRIQ (atezolizumab) - IMmotion151
Kidney cancer - renal cell carcinoma (mRCC)
Approval announced June 7, 2018.
MabThera/ Rituxan (rituximab)
Pemphigus vulgaris
Phase 3 data released July 19, 2018. PFS endpoint met, OS endpoint not yet met - final OS data due 2019.
TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) - IMpower132
Squamous non-small cell lung cancer (NSCLC)
FDA approval announced March 18, 2019.
Tecentriq+cb+etoposide - IMpower133
Squamous non-small cell lung cancer (NSCLC)
PDUFA date for sBLA September 2, 2019.
TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) - IMpower130
Squamous non-small cell lung cancer (NSCLC)
Phase 3 data due 2019.
IMspire150 - cobimetinib, atezolizumab and vemurafenib - TRILOGY
BRAF V600 mutation-positive metastatic or unresectable locally advanced melanoma
FDA Approval announced October 4, 2018.
Hemlibra
Hemophilia
Phase 3 updated data due at 27 September-1 October 2019
Alecensa - ALEX
Anaplastic lymphoma kinase (ALK)-positive metastatic (advanced) non-small cell lung cancer (NSCLC)
Phase 1b trial expansion announced June 1, 2018.
Cabozantinib + atezolizumab (TECENTRIQ) COSMIC-021
Solid tumors
FDA approval announced June 13, 2018.
Avastin (bevacizumab) + chemo
Ovarian cancer
Phase 3 enrollment has commenced - noted June 14, 2018.
Gantenerumab
Early Alzheimer's disease
FDA Approval announced October 24, 2018.
Baloxavir marboxil
Influenza
Phase 3 trial initiation announced July 26, 2018.
Subcutaneous Pertuzumab And Trastuzumab
HER2-positive early breast cancer
FDA approval announced November 21, 2018.
Venclexta
First line unfit AML
FDA approval announced May 15, 2019.
Venetoclax and obinutuzumab
Chronic Lymphocytic Leukemia
FDA Approval announced March 8, 2019.
TECENTRIQ (atezolizumab) plus Abraxane
Triple-negative breast cancer
Phase 3 interim analysis passed.
Tecentriq + chemo - IMpassion 031
Neoadjuvant triple negative breast cancer
Phase 3 data due 2019.
Tecentriq + Avastin - IMbrave 150
Hepatocellular carcinoma
Phase 3 data presented at ASCO June 4, 2019. HR 0.35. CRR 49.5%. ORR 84.7% vs. 71.3%.
Venclexta plus Gazyva
Chronic lymphocytic leukemia (CLL)
Phase 3 data due 2019.
Venclexta MIRROS
Acute myeloid leukemia (AML)
Phase 3 primary endpoint met.
Venclexta BELLINI
Multiple myeloma
FDA approval announced June 10, 2019.
Polatuzumab vedotin and bendamustine plus Rituxan (rituximab)
Diffuse large B-cell lymphoma (DLBCL)
PDUFA date for sNDA November 4, 2019.
Baloxavir marboxil
Influenza
Phase 3 OS update at ASCO June 4, 2019 - median OS=21.0 vs 18.7 months; HR=0.86.
Tecentriq plus nab-paclitaxel - IMpassion 130
Triple-negative breast cancer
Phase 3 data due 2019.
Tecentriq - IMvigor211
Urothelial cancer
Phase 3 data due 2019.
Idasanutlin (RG7388) - MIRROS
Acute myeloid leukemia (AML)
Phase 3 trials met primary endpoints - June 3, 2019.
Xolair (omalizumab)
Chronic rhinosinusitis with nasal polyps (CRSwNP)
PDUFA date under priority review, sBLA accepted June 12, 2019. No PDUFA date released. Estimate October 11, 2019 assuming sBLA was filed two months prior to acceptance.
MabThera/ Rituxan (rituximab)
Granulomatosis with polyangiitis (GPA) / microscopic polyangiitis (MPA)
Phase 3 trial met primary and secondary endpoints - June 13, 2019.
Mabthera/Rituxan (rituximab) - PEMPHIX
Pemphigus vulgaris

Latest News

  1. The 10 Biggest Biotech Stocks
  2. AbbVie Announces Lifting of FDA's Partial Hold on CANOVA Study
  3. This would be the worst-case scenario for health stocks, according to UBS
  4. Making the finance industry more diverse
  5. Here's how many American households are Amazon Prime members
  6. Oh, By the Way, This Clinical Trial Didn't Work
  7. Pharma Stock Roundup: PFE to Buy ARRY, RHHBY, MRK, AZN Drugs Get Regulatory Nod
  8. Sanofi Partners Google to Build Healthcare Innovation Lab
  9. Roche's Rozlytrek Gets Approval in Japan for Solid Tumors
  10. Japan becomes the first country to approve Roche’s personalised medicine Rozlytrek
  11. Bayer to Invest 5 Billion Euros in Weedkiller Research
  12. Why This Gene Therapy Stock Looks Like A Sure Takeover Bet: Analyst
  13. These Were The Most Actively Traded Securities On The OTC Markets In May
  14. AstraZeneca Gives Detailed Data From Calquence Leukemia Study
  15. Why Alzheimer's Treatment Hopes Endure Despite High-Profile Drug Failures
  16. Pharma Stock Roundup: MRK Buys Small Cancer Biotech, RHHBY, MRK Drugs Get FDA Nod
  17. Amgen/Allergan Get FDA Nod for Herceptin Biosimilar Kanjinti
  18. Mallinckrodt Presents Encouraging Data on Acthar Gel for RA
  19. Roche Reports Positive Data on Rituxan for Pemphigus Vulgaris
  20. The Daily Biotech Pulse: Savara Slumps On Flunked Trial, NuCana Takes Off, Tetraphase Downsizes